株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

敗血症診断薬:世界市場の予測と分析、検査技術別 (2020~2024年)

SEPSIS DIAGNOSTICS Global Markets by Assay Technology with Executive and Consultant Guides. Including Customized Forecasting and Analysis 2020 to 2024

発行 Howe Sound Research 商品コード 914655
出版日 ページ情報 英文 237 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
敗血症診断薬:世界市場の予測と分析、検査技術別 (2020~2024年) SEPSIS DIAGNOSTICS Global Markets by Assay Technology with Executive and Consultant Guides. Including Customized Forecasting and Analysis 2020 to 2024
出版日: 2019年11月03日 ページ情報: 英文 237 Pages
概要

当レポートでは、世界と米国の敗血症診断薬の市場について分析し、疾患の概略や業界の基本構造・背景事情、主な市場促進・抑制要因、近年の研究開発の動き、主要企業のプロファイル、全体的な市場規模の動向と見通し (今後5年間分)、診断手法別・製品別の詳細動向、といった情報を取りまとめてお届けいたします。

分析概略

第1章 イントロダクションと市場定義

  • 敗血症診断薬の概要
  • 市場の定義
  • 分析手法
  • 米国の医療市場と臨床検査 - 展望
    • 米国における臨床検査向けMedicare支出額

第2章 敗血症 - 現在の治療水準

  • 敗血症とは何か?
    • 臓器傷害
    • 新生児の敗血症
    • 予後
  • 診断方法
    • 感染の判定
    • バイオマーカー
    • 様々な診断方法
  • 敗血症の病因
    • 敗血症の進行
  • 有病者数

第3章 産業概要

  • ダイナミックな市場における企業
    • 教育機関
    • 診断検査法の開発企業
    • 医薬品/試薬サプライヤー
    • 独立系臨床検査室
    • 政府機関
    • 病院
    • 開業医
    • 監査機関
    • 認証機関

第4章 市場動向

  • 成長促進要因
    • 有病者の増加
    • 薬剤耐性 (AMR)
    • 診断件数の増加
    • マルチプレックス診断の影響
    • 世界各国の高齢化
    • 発展途上国の医療費の拡大
  • 成長抑制要因
    • コスト圧力による市場縮小
    • 診断上のジレンマ
    • 導入時のタイムラグと費用管理
  • 診断技術の開発
    • マルチプレックス診断の機会
    • 診断における医師の役割の変化
    • 検査室以外での診断検査の増加
    • バイオマーカーとアルゴリズム
    • 迅速検査による臨床診療の変化
    • ゲノムの役割とビッグデータ
    • 今後5年間の動向見通し

第5章 敗血症の診断法 - 近年の動向

  • 近年の開発動向 - 重要性と活用方法

第6章 主要企業のプロファイル

  • Abbott Diagnostics
  • Abionic
  • Accel Diagnostics
  • Accelerate Diagnostics
  • Axis-Shield Diagnostics Ltd
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Biocartis
  • bioMerieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Bruker
  • Cube Dx
  • Curetis N.V. / Curetis GmbH
  • Cytovale
  • EKF Diagnostics Holdings
  • GeneFluidics
  • GenMark Dx
  • Grifols
  • Immunexpress
  • Inflammatix
  • Linear Diagnostics
  • Luminex Corp
  • Mbio Diagnostics
  • Mobidiag
  • Nanomix
  • Qiagen Gmbh
  • Response Biomedical
  • Roche Molecular Diagnostics
  • SeLux Diagnostics
  • Septec
  • Siemens Healthineers
  • Sphingotec
  • T2 Biosystems
  • Thermo Fisher Scientific Inc

第7章 敗血症診断薬の市場

  • 敗血症診断薬 - 世界市場の概況、国別

第8章 世界の敗血症診断薬:診断検査の種類別

  • 世界市場:診断薬の種類別 - 概要
  • 敗血症診断薬 - 微生物
  • 敗血症診断薬 - 症候群PoCパネル
  • 敗血症診断薬 - その他の感染症
  • 敗血症診断薬 - バイオマーカー分子診断
  • 敗血症診断薬 - その他のバイオマーカー

第9章 世界の敗血症診断薬市場 - 製品種類別

  • 製品種類別の市場 - 概要
  • 敗血症診断薬 - 診断装置
  • 敗血症診断薬 - 試薬
  • 敗血症診断薬 - ソフトウェア、その他

付録

  • 米国のMedicare制度:臨床検査料金のスケジュール (2019年) - 政府による支出上限と平均支出額
図表

Table of Tables

  • Table 1: Lab Spending 2014 to 2024
  • Table 2: sepsis biomarkers - Established and potential
  • Table 3: Market Players by Type
  • Table 4: Five Factors Driving Growth
  • Table 5: Three Factors Limiting Growth
  • TABLE 6: GLOBAL SEPSIS DIAGNOSTICS MARKET BY COUNTRY/REGION
  • TABLE 7: GLOBAL MARKET BY ASSAY TYPE
  • TABLE 8: SEPSIS DIAGNOSTIC MICROBIOLOGY BY COUNTRY
  • TABLE 9: SEPSIS DIAGNOSTIC SYNDROMIC POC PANEL BY COUNTRY
  • TABLE 10: SEPSIS DIAGNOSTIC OTHER ID BY COUNTRY
  • TABLE 11: SEPSIS DIAGNOSTIC BIOMARKER MDX BY COUNTRY
  • TABLE 12: SEPSIS DIAGNOSTIC BIOMARKER OTHER BY COUNTRY
  • TABLE 13: GLOBAL MARKET BY PRODUCT TYPE
  • TABLE 14: SEPSIS DIAGNOSTIC INSTRUMENTS BY COUNTRY
  • TABLE 15: SEPSIS DIAGNOSTIC REAGENTS BY COUNTRY
  • TABLE 16: SEPSIS DIAGNOSTIC SW & SERV BY COUNTRY
  • Table 17: 2019 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Sepsis Survival graph
  • Figure 2: Percentage of Sepsis Patients with Comorbidity
  • Figure 3: Clinical Lab Spending 2014 to 2024
  • Figure 4: Sepsis Clinical Progression
  • Figure 5: Deaths From Drug Resistant Infections 2050
  • Figure 6: Aggregate Age of World Population
  • Figure 7: Growth in Health Care Spending Developing World
  • Figure 8: Comparing The New Diagnostics and Traditional Testing
  • Figure 9: Growth rates of Sepsis Diagnostics
  • Figure 10: Global Market Density Chart
  • Figure 11: Sepsis Diagnostics Market by Type - 2019 vs. 2024
  • FIGURE 12: SEPSIS DIAGNOSTICS MARKET 2019
  • FIGURE 13: SEPSIS DIAGNOSTICS MARKET 2024
  • FIGURE 14: TYPE SHARE BY YEAR
  • FIGURE 15: SEPSIS DIAGNOSTIC MICROBIOLOGY GROWTH
  • FIGURE 16: SEPSIS DIAGNOSTICS SYNDROMIC POC PANEL GROWTH
  • FIGURE 17: SEPSIS DIAGNOSTIC OTHER INFECTIOUS DISEASE GROWTH
  • FIGURE 18: SEPSIS DIAGNOSTIC MOLECULAR DIAGNOSTICS GROWTH
  • FIGURE 19: SEPSIS DIAGNOSTIC BIOMARKER OTHER GROWTH
  • Figure 20: Sepsis Diagnostics Market by Product Type - 2019 vs. 2024
  • FIGURE 21: SEPSIS DIAGNOSTICS MARKET BY PRODUCT TYPE BASE YEAR
  • FIGURE 22: SEPSIS DIAGNOSTICS MARKET BY PRODUCT TYPE FINAL YEAR
  • FIGURE 23: PRODUCT TYPE SHARE BY YEAR
  • FIGURE 24: SEPSIS DIAGNOSTIC INSTRUMENTS GROWTH
  • FIGURE 25: SEPSIS DIAGNOSTICS HBA1C GROWTH
  • FIGURE 26: SEPSIS DIAGNOSTIC SE & SERVICES GROWTH
目次

OVERVIEW:

Sepsis is killing over 30 million people a year with no definitive diagnostic in hand. The race is on using all the genomic and molecular diagnostic tools that have come to the fore in the last decade. It is not clear who will be the winner, but the stakes are global and large. Emergency life saving diagnostics can command a premium in the market. Understand what is driving this huge global diagnostic market and where the opportunity lies.

Our facts and support = Your success.

The report forecasts the market size out to 2024. Growth is coming from the basic factors but technology and education are creating the awareness needed to rapidly expand the diagnostic market. Some players have already made their mark but disruptive diagnostic technology could change the playing field.. Learn about this market including the issues and outlooks. The two key trends of Rapid Diagnositic and the Genomics Revolution are merging to create new diagnostic opportunities.

Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to a wider license. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Market Guides

  • iA. Situation Analysis
  • iB. Guide for Executives and Marketing Staff
  • iC. Guide for Investment Analysts and Management Consultants

1. Introduction and Market Definition

  • 1.1 An Overview of Sepsis Diagnostics
    • 1.1.1 Sepsis the medical emergency
    • 1.1.2 Sepsis Diagnosis and Comorbidity
  • 1.3 Market Definition
    • 1.3.1 Market Size
    • 1.3.2 Currency
    • 1.3.3 Years
    • 1.3.4 Microbiology
    • 1.3.5 Other Infectious Disease
    • 1.3.6 Syndromic PoC
    • 1.3.7 Biomarkers Molecular Diagnostics
    • 1.3.8 Biomarkers Other
    • 1.3.9 Limitations
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1 U.S. Medicare Expenditures for Laboratory Testing

2. Sepsis - Current Science

  • 2.1 What is Sepsis?
    • 2.1.1 Organ Damage
    • 2.1.2 Neonatal sepsis
    • 2.1.3 Prognosis
  • 2.2 Diagnosis
    • 2.2.1 Infection Identification
    • 2.2.2 Biomarkers
    • 2.2.3 Differential diagnosis
  • 2.3 Causes of Sepsis
    • 2.3.1 Sepsis Progression
  • 2.4 Prevalence

3. Industry Overview

  • 3.1 Players in a Dynamic Market
    • 3.1.1 Academic Research Lab
    • 3.1.2 Diagnostic Test Developer
    • 3.1.3 Pharmaceutical/Reagent Supplier
    • 3.1.4 Independent Testing Lab
    • 3.1.6 Public National/regional lab
    • 3.1.7 Hospital lab
    • 3.1.8 Physician Lab
    • 3.1.9 Audit Body
    • 3.1.10 Certification Body

4. Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 Increasing Prevalence
    • 4.1.2 Antimicrobial Resistance
    • 4.1.3 Increasing Diagnosis
    • 4.1.4 Multiplex Diagnostics Impacts
    • 4.1.5 The Aging World
    • 4.1.6 Developing World Health Care Spending
  • 4.2 Factors Limiting Growth
    • 4.2.1 The Cost Curve Shrinks the Market
    • 4.2.2 The Diagnostics Dillemma
    • 4.2.3 Adoption Lag and Cost Control
  • 4.3 Diagnostic Technology Development
    • 4.3.1 The Multiplex Opportunity
    • 4.3.2 Shifting Role of Physicians in Diagnosis
    • 4.3.3 Diagnostics Moves Out of the Lab
    • 4.3.4 Biomarkers and Algorithms
    • 4.3.5 Rapid Testing Changing Medical Practice
    • 4.3.6 Genome Role and Big Data
    • 4.3.6 The Next Five Years

5. Sepsis Diagnostics - Recent Developments

  • 5.1 Recent Developments - Importance and How to Use This Section
    • 5.1.1 Importance of These Developments
    • 5.1.2 How to Use This Section
      • Abionic: Study Demonstrates Diagnosis of Sepsis in 5 Minutes
      • T2 Biosystems Introduces New Data and Updates for Rapid Diagnostic Technology
      • Sepsis found to fit into 4 subtypes
      • GenMark Diagnostics Receives FDA Clearance for Blood Panel
      • Novacyt, Immunexpress Extend Sepsis Assay Development Partnership
      • New Test Could Diagnose Sepsis Faster
      • Immunexpress Wins $745K HHS Contract for Rapid Sepsis Assay
      • Curetis' Unyvero Application Cartridges Receive Regulatory Approvals
      • Luminex to Pay $75M for MilliporeSigma's Flow Cytometry Research Portfolio
      • Experimental 2.5-minute Sepsis Test Discovered
      • sphingotec raises €20 million
      • SeLux Diagnostics Announces Sepsi U.S. HHS/BARDA Research Funding
      • Roche PCT assay cleared as tool in fight against Sepsis
      • GeneFluidics selected as finalist for AMR Challenge
      • BioDirection, Inc. Announces System to Diagnose and Monitor Sepsis
      • sphingotec Adding Advanced POC Testing Platform
      • Rapid Detection Using DNAe's LiDia® Bloodstream Infection Technology
      • Septec Team Working on 15 Minute Sepsis Diagnosis
      • Abionic Announces Rapid Sepsis PoC Diagnostic

6. Profiles of Key Companies

  • Abbott Diagnostics
  • Abionic
  • Accel Diagnostics
  • Accelerate Diagnostics
  • Axis-Shield Diagnostics Ltd
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Biocartis
  • bioMérieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Bruker
  • Cube Dx
  • Curetis N.V. / Curetis GmbH
  • Cytovale
  • EKF Diagnostics Holdings
  • GeneFluidics
  • GenMark Dx
  • Grifols
  • Immunexpress
  • Inflammatix
  • Linear Diagnostics
  • Luminex Corp
  • Mbio Diagnostics
  • Mobidiag
  • Nanomix
  • Qiagen Gmbh
  • Response Biomedical
  • Roche Molecular Diagnostics
  • SeLux Diagnostics
  • Septec
  • Siemens Healthineers
  • Sphingotec
  • T2 Biosystems
  • Thermo Fisher Scientific Inc

7. Sepsis Diagnostic Markets

  • 7.1 Sepsis Diagnostics - Global Market Overview by Country
    • 7.1.1 Table - Global Market by Country
    • 7.1.2 Chart - Global Market by Country

8. Global Sepsis Diagnostics Markets - By Assay Type

  • 8.1 Global Market by Diagnostic Type - Overview
    • 8.1.1 Table - Global Market by Diagnostic Type
    • 8.1.2 Chart - Global Market by Assay Type
    • 8.1.3 Chart - Global Market by Type - 2019
    • 8.1.4 Chart - Global Market by Type -2024
    • 8.1.4 Chart - Global Market by Type - Share by Year
  • 8.2 Sepsis Diagnostic - Microbiology
    • 8.2.1 Table Sepsis Diagnostic Microbiology - by Country
    • 8.2.2 Chart - Sepsis Diagnostic Microbiology Growth
  • 8.3 Sepsis Diagnostic - Syndromic PoC Panel
    • 8.3.1 Table Sepsis Diagnostic Syndromic PoC Panel - by Country
    • 8.3.2 Chart - Sepsis Diagnostic Syndromic PoC Panel Growth
  • 8.4 Sepsis Diagnostic - Other Infectious Disease
    • 8.4.1 Table Sepsis Diagnostic Other ID - by Country
    • 8.4.2 Chart - Sepsis Diagnostic - Other Infectious Disease Growth
  • 8.5 Sepsis Diagnostic - Biomarker Molecular Diagnostic
    • 8.5.1 Table Sepsis Diagnostic Biomarker MDx - by Country
    • 8.5.2 Chart - Sepsis Diagnostic - Biomarker MDx Growth
  • 8.6 Sepsis Diagnostic - Biomarker Other
    • 8.6.1 Table Sepsis Diagnostic Biomarker Other - by Country
    • 8.6.2 Chart - Sepsis Diagnostic - Biomarker Other Growth

9. Global Sepsis Diagnostics Markets - By Product Type

  • 9.1 Global Market by Product Type - Overview
    • 9.1.1 Table - Global Market by Product Type
    • 9.1.2 Chart - Global Market by Product Type - 2019/2024 Comparison
    • 9.1.3 Chart - Global Market by Product Type - Base Year
    • 9.1.4 Chart - Global Market by Product Type - Final Year
    • 9.1.4 Chart - Global Market by Product Type - Share by Year
  • 9.2 Sepsis Diagnostic - Instruments
    • 9.2.1 Table Sepsis Diagnostic Instruments - by Country
    • 9.2.2 Chart - Sepsis Diagnostic Instruments Growth
  • 9.3 Sepsis Diagnostic - Reagents
    • 9.3.1 Table Sepsis Diagnostic Reagents - by Country
    • 9.3.2 Chart - Sepsis Diagnostic Reagents Growth
  • 9.4 Sepsis Diagnostic - Software & Service
    • 9.4.1 Table Sepsis Diagnostic SW & Service - by Country
    • 9.4.2 Chart - Sepsis Diagnostic - SW & Services Growth

Appendices

  • I. United States Medicare System: 2019 Clinical Laboratory Fees Schedule - National Limit and Midpoint
Back to Top